NewAmsterdam Pharma (NAMS) News Today $20.03 0.00 (0.00%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$20.02 -0.01 (-0.02%) As of 05/2/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Acuta Capital Partners LLC Makes New $1.29 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Acuta Capital Partners LLC acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $1,285,000. NewAmMay 4 at 7:12 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) is RA Capital Management L.P.'s 7th Largest PositionRA Capital Management L.P. boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,845,000 shares of the company's stock after acquirinMay 3 at 7:48 AM | marketbeat.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2 at 4:01 PM | globenewswire.comMonashee Investment Management LLC Invests $1.29 Million in NewAmsterdam Pharma (NASDAQ:NAMS)Monashee Investment Management LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the company's stock, valueMay 2 at 7:48 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objectMay 2 at 4:39 AM | marketbeat.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | gurufocus.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comInvesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS)Invesco Ltd. acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 150,559 shares of the company's stock, valued at approximApril 29, 2025 | marketbeat.comDecheng Capital LLC Has $19.79 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Decheng Capital LLC raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 30.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 770,000 shares of the company's stock after purchasing an addiApril 28, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 330,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Adage Capital Partners GP L.L.C. lessened its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,050,000 shares of the company's stock afteApril 28, 2025 | marketbeat.comWalleye Capital LLC Has $270,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)Walleye Capital LLC decreased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 77.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,506 shares of the company's stock after selling 36,441 shApril 28, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 172.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,977 shares of the company's stock after purchasing an additiApril 28, 2025 | marketbeat.comGMT Capital Corp Has $7.33 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)GMT Capital Corp cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 65.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 285,136 shares of the company's stock after selling 543,900 shares during the period. NewAmsterdam PharmApril 25, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Marshall Wace LLPMarshall Wace LLP raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 161.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,446 shares of the company's stock after purchasing an additionalApril 25, 2025 | marketbeat.comJump Financial LLC Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Jump Financial LLC purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,401 shares of the company's stock, valued atApril 25, 2025 | marketbeat.comSlate Path Capital LP Purchases New Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Slate Path Capital LP acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 319,000 shares of the company's stock, valued at approximately $8,198,000. Slate Path Capital LP owned approximatApril 24, 2025 | marketbeat.comEversept Partners LP Sells 31,995 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Eversept Partners LP lessened its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 275,362 shares of the company's stock after selling 31,995 shares duringApril 24, 2025 | marketbeat.com1,016,076 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by Capital World InvestorsCapital World Investors acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,016,076 shares of the company's stock, valueApril 24, 2025 | marketbeat.comIs NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23, 2025 | insidermonkey.comRock Springs Capital Management LP Purchases 414,203 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Rock Springs Capital Management LP increased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 117.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 767,522 shares of theApril 23, 2025 | marketbeat.comBain Capital Life Sciences Investors LLC Acquires 245,197 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Bain Capital Life Sciences Investors LLC boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,719,110 shares of the company's stock after acquiring an additApril 23, 2025 | marketbeat.comCapital International Investors Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Capital International Investors acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,062,535 sharesApril 23, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Short Interest UpdateNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 5,340,000 shares, an increase of 23.0% from the March 15th total of 4,340,000 shares. Based on an average daily volume of 996,300 shares, the short-interest ratio is presently 5.4 days. Approximately 9.4% of the company's shares are sold short.April 22, 2025 | marketbeat.comNewAmsterdam Pharma Appoints Adele Gulfo to BoardApril 17, 2025 | tipranks.comNewAmsterdam Pharma Appoints Adele Gulfo to its Board of DirectorsApril 17, 2025 | gurufocus.comNewAmsterdam Pharma Co NV (NAMS) Appoints Adele Gulfo to Board of Directors | NAMS stock newsApril 17, 2025 | gurufocus.comAffinity Asset Advisors LLC Sells 47,390 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Affinity Asset Advisors LLC lowered its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 425,000 shares of the company's stock after selling 47,April 17, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)Arrowstreet Capital Limited Partnership bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 30,504 shares of the company's stock, valued at approximateApril 14, 2025 | marketbeat.comNewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside PotentialApril 11, 2025 | msn.comCenterBook Partners LP Purchases 122,894 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)CenterBook Partners LP increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 143.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,589 shares of the company's stock after acquiriApril 11, 2025 | marketbeat.comNewAmsterdam Pharma's (NAMS) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday.April 10, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Receives a Buy from TD CowenApril 9, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comNewAmsterdam Pharma Company (NAMS) Gets a Buy from NeedhamApril 9, 2025 | markets.businessinsider.com4NAMS : The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 ExpertsApril 8, 2025 | benzinga.comOvata Capital Management Ltd Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)Ovata Capital Management Ltd purchased a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 150,000 shares of the company's stock, valued at aApril 7, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Recommendation of "Buy" from AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued aApril 7, 2025 | marketbeat.comAlliancebernstein L.P. Acquires New Stake in NewAmsterdam Pharma (NASDAQ:NAMS)Alliancebernstein L.P. bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,858,065 shares of the company's stock, valued at approximately $47,7April 7, 2025 | marketbeat.comWellington Management Group LLP Acquires 2,222,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Wellington Management Group LLP raised its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 2,410.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,315,123 shares of the company's stock after acquiring an additionaApril 7, 2025 | marketbeat.comPamalican Asset Management Ltd Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Pamalican Asset Management Ltd purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 30,000 shares of the company's stoApril 6, 2025 | marketbeat.comCinctive Capital Management LP Sells 57,055 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Cinctive Capital Management LP trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 85.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,516 shares of the company's stock after selling 57,055 shares during the qApril 6, 2025 | marketbeat.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options for New HiresApril 4, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2025 | globenewswire.comAmerican Century Companies Inc. Acquires Shares of 346,572 NewAmsterdam Pharma (NASDAQ:NAMS)American Century Companies Inc. acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 346,572 shares of the coApril 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - Here's WhyNewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume Increase - Here's WhyApril 3, 2025 | marketbeat.comNewAmsterdam Pharma is Now Oversold (NAMS)April 3, 2025 | nasdaq.comNAMS Crosses Below Key Moving Average LevelApril 2, 2025 | nasdaq.comPiper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)April 2, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Time to Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 8.5% - Here's What HappenedApril 1, 2025 | marketbeat.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼1.280.73▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼135▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Lantheus News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Sarepta Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News ADMA Biologics News Blueprint Medicines News Verona Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts